Skip to main content
    Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
    Share:X PostLinkedIn
    Hormonal & Endocrine•Updated 2026-02-01•4 min read

    What Is PEG-MGF? Benefits, Research & Safety

    A PEGylated version of mechano growth factor with extended half-life, researched for muscle repair and hypertrophy.

    Share:X PostLinkedIn
    Also known as:
    PEGylated Mechano Growth Factor
    PEGylated IGF-1Ec
    ETheoretical / insufficientUK: Unlicensed (UK)WADA: Prohibited in sport

    UK summary: Not a licensed UK medicine. A PEGylated form of mechano growth factor (an IGF-1 splice variant). Prohibited at all times under WADA S2. Human evidence in the marketed muscle-recovery context is essentially absent.

    Quick Facts

    Category
    Hormonal & Endocrine
    Half-Life
    Extended to hours (vs minutes for native MGF); exact duration varies
    UK Status
    Not licensed. Research compound only. Prohibited in sport.
    EU Status
    Not approved for any indication.

    Overview

    PEG-MGF (PEGylated Mechano Growth Factor) is a modified form of mechano growth factor, itself a splice variant of IGF-1 (Insulin-like Growth Factor 1). The PEGylation process attaches polyethylene glycol chains to the peptide, dramatically extending its biological half-life. Mechano Growth Factor (MGF, also known as IGF-1Ec) is naturally produced in muscle tissue in response to mechanical stress or damage. It plays a crucial role in muscle repair and adaptation to exercise by activating satellite cells (muscle stem cells) and promoting tissue regeneration. Native MGF has an extremely short half-life of only a few minutes, limiting its practical research applications. PEGylation extends this half-life to potentially hours or days, making PEG-MGF more suitable for research applications and increasing systemic effects compared to local MGF production. PEG-MGF has attracted interest in the sports and bodybuilding research community for its potential muscle-building and recovery-enhancing properties. However, it remains a research compound with limited human data and significant unknowns regarding safety. PEG-MGF is not approved for human use and is prohibited in sport by WADA as part of the IGF-1 family of compounds.
    Evidence standards summary

    PEG-MGF — evidence and risk at a glance

    Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

    01Evidence snapshot

    Not a licensed UK medicine. A PEGylated form of mechano growth factor (an IGF-1 splice variant). Prohibited at all times under WADA S2. Human evidence in the marketed muscle-recovery context is essentially absent.

    02Human evidence grade

    ETheoretical / insufficientStrength of evidence from published human trials.

    03Preclinical evidence grade

    CLimited human evidenceAnimal-model and in-vitro evidence quality.

    04Regulatory status

    • UK: Not licensed. Research compound only. Prohibited in sport.
    • EU: Not approved for any indication.
    • Notes: PEG-MGF is not approved for human use anywhere in the world. It is prohibited by WADA as part of the IGF-1 family. Products available are from research chemical suppliers and are unregulated.

    05Approved medical uses

    None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)

    06Unapproved / promotional claims

    • Builds muscle locally where injected.
    • Repairs damaged muscle faster than rest and protein.
    • Safe for daily long-term injection.
    • Undetectable by drug tests.

    07Common internet claims

    • Marketed in bodybuilding stacks alongside IGF-1 LR3 and CJC-1295.
    • Sold by online retailers as a research-only injectable.
    • Promoted for 'site injection' to grow specific muscles.

    08Claim vs evidence

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “Activates satellite cells for accelerated muscle repair”ENoHighMechanistic plausibility exists from the MGF splice variant literature; human evidence for the commercially-sold PEG-MGF is absent.
    “Safer than HGH for muscle building”ENoHighComparative-safety claims need human trial data; none exists.
    “Legal because it's not a steroid”ENoHighProhibited at all times under WADA S2 alongside other IGF-1 / growth-factor analogues.

    09Safety uncertainty score

    Very high

    Effectively no human safety data; safety claims are extrapolations from animal work or anecdote.

    10Known adverse signals

    • Theoretical oncologic risk from sustained IGF-1-pathway activation.
    • Joint pain and water retention reported anecdotally.
    • Injection-site reactions.
    • Unknown chronic effects of supraphysiological MGF signalling.

    11Drug-interaction uncertainty

    High

    Interaction picture sparse; meaningful uncertainty when combined with other medicines.

    12Anti-doping status

    WADA: Prohibited in sportWADA strict-liability framing applies.

    13UK legal position

    UK: Unlicensed (UK)

    Not licensed. Research compound only. Prohibited in sport.

    Read the full UK legal guide → Peptides and athletes (UK)

    14EU legal position

    Not approved for any indication.

    15What this page cannot tell you

    • Whether a UK-purchased vial contains PEG-MGF at the labelled concentration.
    • Whether 'site injection' produces meaningful local hypertrophy in humans.
    • Long-term oncologic risk from chronic use.
    • WADA detection windows — assume positive on test, prohibition is strict-liability.

    16Last reviewed

    Last reviewed:

    Next review due:

    Spotted an error or something out of date? Send a correction.

    17Citation quality score

    DAnimal/cell evidence onlyQuality of the sources we cite, graded against the evidence grading methodology.

    18Research gaps

    • No registered Phase 2 or 3 trials in humans for any indication.
    • Body-composition outcome data in humans absent.
    • Long-term safety entirely unstudied.
    • Combination-stack safety uncharacterised.

    19Safer alternatives / established care pathways

    • Progressive resistance training with adequate protein and recovery — the only evidence-based muscle-growth intervention.
    • GP review for testosterone or growth-hormone deficiency where clinically suspected.
    • Licensed mecasermin (Increlex) only for severe primary IGF-1 deficiency under specialist.

    Related Safety Centre page → Athlete anti-doping risks

    20Doctor discussion prompts

    Questions to ask a qualified clinician

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • Is PEG-MGF a licensed UK medicine?
    • What is the human-outcomes evidence?
    • If I'm an athlete, what is the WADA position?

    Discovery & History

    Mechano Growth Factor was identified in the 1990s and early 2000s as a splice variant of the IGF-1 gene expressed specifically in muscle tissue following mechanical loading or damage. Research by Professor Geoffrey Goldspink at University College London was instrumental in characterising MGF. Studies showed that MGF expression was one of the earliest responses to muscle damage and mechanical stress, preceding the expression of IGF-1Ea (the hepatic, systemic form of IGF-1). This suggested a specific role in local muscle repair and adaptation. The extremely short half-life of MGF (minutes) in circulation limited its research applications beyond local injection studies. Scientists developed PEGylated versions to extend the half-life through the addition of polyethylene glycol chains, a technique widely used in pharmaceutical development. PEG-MGF allowed researchers to study the effects of MGF signaling over longer periods and with systemic rather than just local effects. However, it's important to note that this changes the pharmacology significantly from natural, locally-produced MGF. The peptide became available through research chemical suppliers and gained attention in bodybuilding communities. No clinical development for therapeutic applications has been publicly announced.

    Mechanism of Action

    PEG-MGF works through activation of the IGF-1 receptor, with specific properties related to its structure: **Satellite Cell Activation** A primary effect of MGF is activation of muscle satellite cells: - Stimulates proliferation of satellite cells - Promotes their differentiation into mature muscle cells - May contribute to muscle hyperplasia (new fibre formation) in addition to hypertrophy - Important for muscle repair following injury **IGF-1 Receptor Activation** As an IGF-1 splice variant, MGF activates the IGF-1 receptor: - Triggers PI3K/Akt and MAPK signaling pathways - Promotes protein synthesis - Has anti-catabolic effects - Supports cell survival and inhibits apoptosis **PEGylation Effects** The polyethylene glycol modification: - Dramatically extends half-life from minutes to potentially hours - Reduces immunogenicity - Changes distribution from local to more systemic effects - May alter receptor binding characteristics **Differences from Native MGF** The PEGylated form differs from naturally produced MGF: - Much longer duration of action - Systemic rather than local effects - Constant rather than pulsatile/responsive signaling - Different tissue distribution patterns

    Researched Benefits

    Based on preclinical and clinical research findings:

    • 1
      Activation of muscle satellite cells
    • 2
      Potential enhancement of muscle repair following injury
    • 3
      Extended half-life compared to native MGF
    • 4
      Possible contribution to muscle hyperplasia
    • 5
      Support for muscle adaptation to training
    • 6
      Research tool for studying MGF signaling

    Claim vs Evidence

    How popular claims about PEG-MGF stack up against the current research, graded using our public evidence grading methodology.

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “Activates satellite cells for accelerated muscle repair”ENoHighMechanistic plausibility exists from the MGF splice variant literature; human evidence for the commercially-sold PEG-MGF is absent.
    “Safer than HGH for muscle building”ENoHighComparative-safety claims need human trial data; none exists.
    “Legal because it's not a steroid”ENoHighProhibited at all times under WADA S2 alongside other IGF-1 / growth-factor analogues.

    Theoretical Dosing & Protocols

    ⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
    Theoretical Dosage200-400 mcg per administration (extrapolated from research literature)
    FrequencyBilaterally at injection sites, 2-3 times weekly
    Duration4-6 weeks commonly cited in research settings
    Notes⚠️ PEG-MGF is not approved for human use. These are theoretical protocols from research literature and anecdotal reports. Local injection at muscle sites has been common in research settings. Safety and efficacy in humans is not established.

    Administration Routes

    Routes studied in research settings (educational only):

    • Intramuscular injection (typically at target muscle sites)
    • Subcutaneous injection (some protocols)
    Half-LifeStability
    Extended to hours (vs minutes for native MGF); exact duration variesLyophilised powder should be stored at -20°C; reconstituted solution refrigerated and used promptly

    Safety Profile & Known Risks

    Commonly Reported Side Effects

    • Injection site reactions
    • Potential hypoglycaemia (IGF-1 family effects)
    • Localised pain or swelling
    • Limited human safety data available

    Rare Risks & Concerns

    • Unknown long-term effects
    • Potential effects on tumour growth (growth factor)
    • Systemic effects may differ from local MGF production
    • Immune reactions to PEGylated proteins

    Contraindications

    • Active or history of cancer
    • Diabetes or hypoglycaemic tendency
    • Pregnancy and breastfeeding
    • Children and adolescents
    • Known allergies to PEGylated products

    UK & EU Regulatory Context

    🇬🇧 United Kingdom

    Not licensed. Research compound only. Prohibited in sport.

    🇪🇺 European Union

    Not approved for any indication.

    PEG-MGF is not approved for human use anywhere in the world. It is prohibited by WADA as part of the IGF-1 family. Products available are from research chemical suppliers and are unregulated.

    Clinical Studies Summary

    The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

    We summarise structural characteristics, pharmacologic effects, and commonly reported dosing patterns, and we synthesise clinically relevant adverse effects with particular attention to hormonal imbalance, endocrine-metabolic risk, and biologically plausible but unproven mitogenic concerns.

    Front Endocrinol (Lausanne). 2026View on PubMed

    Looking for PEG-MGF?

    Source research-grade PEG-MGF from a trusted UK supplier — third-party tested with certificate of analysis.

    View at Supplier

    Frequently Asked Questions

    Questions to ask a qualified clinician about PEG-MGF

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • Is PEG-MGF a licensed UK medicine?
    • What is the human-outcomes evidence?
    • If I'm an athlete, what is the WADA position?

    UK regulatory & safety context

    Related Peptides

    Explore More Peptides

    Browse our comprehensive database of research-backed peptide profiles.